Chimeric Antigen Receptor News and Research

RSS

Engineered CAR-T cells show promise against glioblastoma in preclinical models

With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.

20 Nov 2025

MD Anderson launches historic $2.5 billion campaign to end cancer

The University of Texas MD Anderson Cancer Center today launches its historic $2.5 billion comprehensive philanthropic campaign, Only Possible Here, The Campaign to End Cancer.

14 Nov 2025

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite standard care involving surgery, radiation, and temozolomide chemotherapy.

30 Oct 2025

AI indelibly transforms solid tumor drug development

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development.

29 Oct 2025

New type of immunotherapy could change the treatment plan for triple-negative breast cancer

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.

22 Oct 2025

Researchers develop a novel approach to monitor CD8⁺ T cell activity over time

The ability of immune cells-particularly CD8+ T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies.

21 Oct 2025

Study explores how losing the Y chromosome fuels bladder cancer aggressiveness

University of Arizona Cancer Center researchers will study the potential effects of the loss of the Y chromosome in the development and progression of bladder cancer thanks to a grant of up to $6.5 million over seven years from the National Cancer Institute.

14 Oct 2025

How shifting antibodies fuel aging and the new therapies aiming to slow it

This review uncovers how aging reshapes immunoglobulins, particularly IgG, IgM, and IgA, driving inflammation, cellular senescence, and tissue degeneration. By dissecting B-cell dysfunction, glycosylation changes, and Fc receptor pathways, it reveals immunoglobulins as both biomarkers and potential therapeutic targets in aging.

14 Oct 2025

Engineered CAR-NK cells show enhanced cancer killing and immune evasion

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be programmed to attack cancer cells.

8 Oct 2025

Engineered CAR T cells show promise against solid tumors

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers.

2 Oct 2025

Genetic modification enhances "living drugs" for blood cancers

CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in modern medicine. Equipping T cells, a key cell type of the immune system, with a "chimeric antigen receptor" (CAR) enables them to specifically recognize and attack cancer cells.

25 Sep 2025

The 15th AACR cancer progress report highlights scientific advances

The American Association for Cancer Research (AACR) released the 15th edition of its annual Cancer Progress Report. A cornerstone of the AACR's educational and advocacy efforts, this comprehensive report provides the latest statistics on cancer incidence, mortality, and survivorship and highlights how federal investments in basic, translational, and clinical cancer research and cancer-related population sciences have led to impressive scientific advances that are improving health and saving lives.

17 Sep 2025

SwRI and UT San Antonio advance biosensor coating to streamline production of immunotherapies

Southwest Research Institute (SwRI) and The University of Texas at San Antonio (UT San Antonio) are advancing a smart biosensor coating to streamline the production of immunotherapies for cancer treatments.

15 Sep 2025

A universal solution emerges: Anti-linker antibodies simplify CAR-T detection and development

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid tumors.

From Sino Biological Inc. 13 Sep 2025

New off-the-shelf immunotherapy for metastatic kidney cancer could help improve outcomes

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective environment - all without the need to customize treatment for each individual patient.

29 Aug 2025

New genome-wide CRISPR screening tool boosts natural killer cells to fight cancer

Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research from The University of Texas MD Anderson Cancer Center.

21 Aug 2025

Special robot hunts for the perfect cancer warriors

Cancer patients can regain full health with immunotherapy. Now researchers are hunting for the perfect immune cell with the help of a very special robot.

18 Aug 2025

New computational tool enhances CAR T cell therapy for hard-to-treat cancers

A computational approach by St. Jude Children's Research Hospital scientists promises to make designing T cell-based immunotherapies that target two cancer-related antigens at the same time far easier and faster.

13 Aug 2025

Early-career physician-scientists receive major support from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

14 Jul 2025

Study unveils powerful strategy to rejuvenate effectiveness of CAR T cell therapy against glioblastoma

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the effectiveness of chimeric antigen receptor (CAR) T cell therapy against glioblastoma, one of the most lethal and treatment-resistant brain tumors.

3 Jul 2025